Peak Financial Advisors LLC Has $1.86 Million Stake in Boston Scientific Corporation $BSX

Peak Financial Advisors LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 191.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,470 shares of the medical equipment provider’s stock after purchasing an additional 12,788 shares during the quarter. Peak Financial Advisors LLC’s holdings in Boston Scientific were worth $1,856,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in BSX. Steph & Co. acquired a new position in Boston Scientific in the 3rd quarter valued at approximately $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Finally, United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BSX. National Bank Financial set a $115.00 price objective on Boston Scientific in a report on Monday, February 2nd. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. The Goldman Sachs Group set a $99.00 price target on Boston Scientific in a research note on Thursday, February 5th. Mizuho reduced their price target on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, Weiss Ratings cut Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $106.27.

Boston Scientific Stock Up 2.3%

BSX stock opened at $69.70 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market cap of $103.59 billion, a PE ratio of 35.93, a PEG ratio of 1.05 and a beta of 0.69. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50. The company has a fifty day simple moving average of $78.22 and a 200 day simple moving average of $91.25.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the company earned $0.70 earnings per share. The business’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis pieces argue BSX may be due for a rebound and potential rating upside, which can attract buyers hunting a recovery after the pullback. Article Title
• Positive Sentiment: Commentary framing the recent decline as a buying opportunity — bullish theses and newsletter coverage are drawing attention from value/turnaround investors. Article Title
• Positive Sentiment: Independent bullish write-ups (summarizing growth prospects and valuation) are circulating and may be supporting dip-buying. Article Title
• Neutral Sentiment: Erste Group marginally trimmed its FY2027 EPS forecast (from $3.92 to $3.91) — a tiny cut that is unlikely to materially change earnings expectations. (Research note issued March 24)
• Neutral Sentiment: Healthcare-sector news (e.g., recognition of smaller device companies for innovation) is present but not directly tied to Boston Scientific’s fundamentals. Article Title
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in a securities class action covering the July 23, 2025–Feb 3, 2026 period; the wave of filings (Rosen, Pomerantz, Levi & Korsinsky, Faruqi, Glancy, Robbins Geller, Bernstein, etc.) increases litigation uncertainty and potential legal costs. Representative notices: Rosen (Newsfile), Levi & Korsinsky (GlobeNewswire), Faruqi & Faruqi. Rosen Notice Levi & Korsinsky Bronstein Notice

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.